Which has better valuation & earnings, TTRX or CADL?

Turn Therapeutics is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Turn Therapeutics N/A N/A -$3.19M -$0.19 N/A Candel Therapeutics N/A N/A -$38.18M -$0.98 N/A

Is TTRX or CADL more profitable?

Turn Therapeutics' return on equity of 0.00% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Turn Therapeutics N/A N/A N/A Candel Therapeutics N/A -60.42% -41.33%

Does the media prefer TTRX or CADL?

In the previous week, Candel Therapeutics had 2 more articles in the media than Turn Therapeutics. MarketBeat recorded 5 mentions for Candel Therapeutics and 3 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 0.94 beat Candel Therapeutics' score of 0.83 indicating that Turn Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor VALN or TTRX?

In the previous week, Valneva had 2 more articles in the media than Turn Therapeutics. MarketBeat recorded 5 mentions for Valneva and 3 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 0.94 beat Valneva's score of 0.38 indicating that Turn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Turn Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, TTRX or TECX?

Turn Therapeutics is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Turn Therapeutics N/A N/A -$3.19M -$0.19 N/A Tectonic Therapeutic N/A N/A -$74.15M -$4.46 N/A

Is TTRX or TECX more profitable?

Turn Therapeutics' return on equity of 0.00% beat Tectonic Therapeutic's return on equity. Company Net Margins Return on Equity Return on Assets Turn Therapeutics N/A N/A N/A Tectonic Therapeutic N/A -32.33% -30.92%

Does the media favor TTRX or TECX?

In the previous week, Turn Therapeutics and Turn Therapeutics both had 3 articles in the media. Turn Therapeutics' average media sentiment score of 0.94 beat Tectonic Therapeutic's score of 0.62 indicating that Turn Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is AQST or TTRX more profitable?

Turn Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%. Company Net Margins Return on Equity Return on Assets Aquestive Therapeutics -137.08% N/A -49.33% Turn Therapeutics N/A N/A N/A

Which has preferable valuation & earnings, KYTX or TTRX?

Turn Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kyverna Therapeutics N/A N/A -$161.31M -$3.28 N/A Turn Therapeutics N/A N/A -$3.19M -$0.19 N/A

Is KYTX or TTRX more profitable?

Turn Therapeutics' return on equity of 0.00% beat Kyverna Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Kyverna Therapeutics N/A -81.88% -64.87% Turn Therapeutics N/A N/A N/A

Does the media prefer KYTX or TTRX?

In the previous week, Kyverna Therapeutics and Kyverna Therapeutics both had 3 articles in the media. Turn Therapeutics' average media sentiment score of 0.94 beat Kyverna Therapeutics' score of 0.63 indicating that Turn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyverna Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Turn Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Turn Therapeutics (TTRX) Competitors

$6.33 +1.13 (+21.73%)

Closing price 06/1/2026 04:00 PM Eastern

Extended Trading

$6.32 -0.01 (-0.24%)

As of 06/1/2026 07:56 PM Eastern

Compare

TTRX vs. CADL, VALN, TECX, AQST, and KYTX

Should you buy Turn Therapeutics stock or one of its competitors? MarketBeat compares Turn Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Turn Therapeutics include Candel Therapeutics (CADL), Valneva (VALN), Tectonic Therapeutic (TECX), Aquestive Therapeutics (AQST), and Kyverna Therapeutics (KYTX). These companies are all part of the "pharmaceutical products" industry.

How does Turn Therapeutics compare to Candel Therapeutics?

Turn Therapeutics (NASDAQ:TTRX) and Candel Therapeutics (NASDAQ:CADL) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

Turn Therapeutics' return on equity of 0.00% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	N/A	N/A
Candel Therapeutics	N/A	-60.42%	-41.33%

Turn Therapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 26.38%. Candel Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 111.52%. Given Candel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Candel Therapeutics is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

13.9% of Candel Therapeutics shares are held by institutional investors. 14.3% of Candel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Candel Therapeutics had 2 more articles in the media than Turn Therapeutics. MarketBeat recorded 5 mentions for Candel Therapeutics and 3 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 0.94 beat Candel Therapeutics' score of 0.83 indicating that Turn Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Turn Therapeutics is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

Summary

Candel Therapeutics beats Turn Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Turn Therapeutics compare to Valneva?

Valneva (NASDAQ:VALN) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Turn Therapeutics has a net margin of 0.00% compared to Valneva's net margin of -88.87%. Turn Therapeutics' return on equity of 0.00% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-88.87%	-107.63%	-33.02%
Turn Therapeutics	N/A	N/A	N/A

Valneva presently has a consensus target price of $11.98, indicating a potential upside of 101.26%. Turn Therapeutics has a consensus target price of $8.00, indicating a potential upside of 26.38%. Given Valneva's stronger consensus rating and higher possible upside, equities research analysts clearly believe Valneva is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

11.4% of Valneva shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Valneva had 2 more articles in the media than Turn Therapeutics. MarketBeat recorded 5 mentions for Valneva and 3 mentions for Turn Therapeutics. Turn Therapeutics' average media sentiment score of 0.94 beat Valneva's score of 0.38 indicating that Turn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Turn Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Turn Therapeutics has lower revenue, but higher earnings than Valneva. Turn Therapeutics is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.86	-$130.33M	-$1.87	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A

Summary

Valneva beats Turn Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Turn Therapeutics compare to Tectonic Therapeutic?

Turn Therapeutics (NASDAQ:TTRX) and Tectonic Therapeutic (NASDAQ:TECX) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

Turn Therapeutics currently has a consensus target price of $8.00, indicating a potential upside of 26.38%. Tectonic Therapeutic has a consensus target price of $80.67, indicating a potential upside of 179.22%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, analysts plainly believe Tectonic Therapeutic is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00

Turn Therapeutics' return on equity of 0.00% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	N/A	N/A
Tectonic Therapeutic	N/A	-32.33%	-30.92%

62.6% of Tectonic Therapeutic shares are held by institutional investors. 39.8% of Tectonic Therapeutic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Turn Therapeutics is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A

In the previous week, Turn Therapeutics and Turn Therapeutics both had 3 articles in the media. Turn Therapeutics' average media sentiment score of 0.94 beat Tectonic Therapeutic's score of 0.62 indicating that Turn Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tectonic Therapeutic	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tectonic Therapeutic beats Turn Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Turn Therapeutics compare to Aquestive Therapeutics?

Aquestive Therapeutics (NASDAQ:AQST) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Turn Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -137.08%.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-137.08%	N/A	-49.33%
Turn Therapeutics	N/A	N/A	N/A

Aquestive Therapeutics currently has a consensus price target of $8.80, indicating a potential upside of 120.00%. Turn Therapeutics has a consensus price target of $8.00, indicating a potential upside of 26.38%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aquestive Therapeutics is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Turn Therapeutics has lower revenue, but higher earnings than Aquestive Therapeutics. Turn Therapeutics is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$50.27M	9.98	-$83.78M	-$0.61	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A

In the previous week, Turn Therapeutics had 2 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 3 mentions for Turn Therapeutics and 1 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 1.89 beat Turn Therapeutics' score of 0.94 indicating that Aquestive Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aquestive Therapeutics	Very Positive
Turn Therapeutics	Positive

32.5% of Aquestive Therapeutics shares are owned by institutional investors. 6.8% of Aquestive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Aquestive Therapeutics beats Turn Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Turn Therapeutics compare to Kyverna Therapeutics?

Kyverna Therapeutics (NASDAQ:KYTX) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

In the previous week, Kyverna Therapeutics and Kyverna Therapeutics both had 3 articles in the media. Turn Therapeutics' average media sentiment score of 0.94 beat Kyverna Therapeutics' score of 0.63 indicating that Turn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyverna Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Turn Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Turn Therapeutics is trading at a lower price-to-earnings ratio than Kyverna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	N/A	N/A	-$161.31M	-$3.28	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A

Kyverna Therapeutics presently has a consensus price target of $30.00, indicating a potential upside of 264.96%. Turn Therapeutics has a consensus price target of $8.00, indicating a potential upside of 26.38%. Given Kyverna Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Kyverna Therapeutics is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Turn Therapeutics' return on equity of 0.00% beat Kyverna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-81.88%	-64.87%
Turn Therapeutics	N/A	N/A	N/A

18.1% of Kyverna Therapeutics shares are held by institutional investors. 17.6% of Kyverna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Kyverna Therapeutics beats Turn Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Turn Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TTRX vs. The Competition

Export

Metric	Turn Therapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$154.90M	$998.00M	$4.38B	$12.56B
Dividend Yield	N/A	4.84%	6.84%	5.30%
P/E Ratio	-33.32	1.47	21.74	26.63
Price / Sales	N/A	130.52	205.21	111.59
Price / Cash	N/A	20.06	57.52	37.60
Price / Book	39.56	8.07	33.85	6.88
Net Income	-$3.19M	-$4.04M	$111.12M	$336.73M
7 Day Performance	18.10%	2.21%	2.06%	3.07%
1 Month Performance	66.58%	88.10%	5.97%	7.13%
1 Year Performance	N/A	124.28%	17.37%	38.42%

Turn Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TTRX Turn Therapeutics	2.4055 of 5 stars	$6.33 +21.7%	$8.00 +26.4%	N/A	$154.90M	N/A	N/A	2	Gap Up High Trading Volume
CADL Candel Therapeutics	3.3082 of 5 stars	$7.93 +2.9%	$18.00 +127.0%	+53.9%	$564.91M	N/A	N/A	60	News Coverage Analyst Upgrade
VALN Valneva	2.4352 of 5 stars	$5.87 -0.8%	$11.98 +104.0%	-5.3%	$561.72M	$197.56M	N/A	700	Analyst Upgrade Gap Up
TECX Tectonic Therapeutic	2.3767 of 5 stars	$28.52 -1.1%	$79.83 +179.9%	+34.3%	$544.19M	N/A	N/A	120	Gap Up
AQST Aquestive Therapeutics	3.1804 of 5 stars	$4.23 +1.4%	$8.80 +108.0%	+48.1%	$523.13M	$44.54M	N/A	160	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TTRX) was last updated on 6/2/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Turn Therapeutics (TTRX) Competitors

TTRX vs. CADL, VALN, TECX, AQST, and KYTX

How does Turn Therapeutics compare to Candel Therapeutics?

Summary

How does Turn Therapeutics compare to Valneva?

Summary

How does Turn Therapeutics compare to Tectonic Therapeutic?

Summary

How does Turn Therapeutics compare to Aquestive Therapeutics?

Summary

How does Turn Therapeutics compare to Kyverna Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTRX vs. The Competition

Turn Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Turn Therapeutics (TTRX) Competitors

TTRX vs. CADL, VALN, TECX, AQST, and KYTX

How does Turn Therapeutics compare to Candel Therapeutics?

Is TTRX or CADL more profitable?

Do analysts rate TTRX or CADL?

Do institutionals & insiders hold more shares of TTRX or CADL?

Does the media prefer TTRX or CADL?

Which has better valuation & earnings, TTRX or CADL?

Summary

How does Turn Therapeutics compare to Valneva?

Is VALN or TTRX more profitable?

Do analysts recommend VALN or TTRX?

Do institutionals & insiders believe in VALN or TTRX?

Does the media favor VALN or TTRX?

Which has preferable earnings and valuation, VALN or TTRX?

Summary

How does Turn Therapeutics compare to Tectonic Therapeutic?

Do analysts recommend TTRX or TECX?

Is TTRX or TECX more profitable?

Do institutionals and insiders believe in TTRX or TECX?

Which has preferable valuation & earnings, TTRX or TECX?

Does the media favor TTRX or TECX?

Summary

How does Turn Therapeutics compare to Aquestive Therapeutics?

Is AQST or TTRX more profitable?

Do analysts prefer AQST or TTRX?

Which has stronger valuation and earnings, AQST or TTRX?

Does the media favor AQST or TTRX?

Do institutionals and insiders have more ownership in AQST or TTRX?

Summary

How does Turn Therapeutics compare to Kyverna Therapeutics?

Does the media prefer KYTX or TTRX?

Which has preferable valuation & earnings, KYTX or TTRX?

Do analysts recommend KYTX or TTRX?

Is KYTX or TTRX more profitable?

Do institutionals & insiders believe in KYTX or TTRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTRX vs. The Competition

Turn Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools